Delivery Order SPE2DB20D2002-SPE2DB23FL21D
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,805.52 firm-fixed-price delivery order contract is for the supply of IPOL VIAL 5ML, a pharmaceutical product. The contract has an ultimate completion date of June 12, 2025. Amerisourcebergen Drug Corp is not designated as a set-aside contractor for this award. Amerisourcebergen Drug Corp...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is a Delivery Order with a Firm Fixed Price of $1,744.16. The contract is for the supply of IPOL VIAL 5ML to the Defense Logistics Agency, a defense agency, with an ultimate completion date of May 29, 2025. The contract is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the Defense...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, is a delivery order worth $21,347.00 for the supply of 4564938215 IPOL VIAL 5ML. The award was made by the Defense Logistics Agency, a defense agency that provides logistics, acquisition, and technical services to the U.S. Armed Forces and other government agencies. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $1,163.64 firm fixed-price delivery order is for the supply of IPOL VIAL 5ML pharmaceutical products. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order (SPE2DB20D2104|SPE2DB24FT00S) valued at $1,182.71 for pharmaceutical products. The contract was awarded by the Defense Logistics Agency (DLA) and has an ultimate completion date of April 2, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for...
- This federal contract award, valued at $16,010.25, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of 4564856969 IPOL VIAL 5ML, a pharmaceutical product, with a completion date of June 11, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31,...
- This federal contract award is a delivery order valued at $1,253.28 awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA). The contract is for the provision of pharmaceutical and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the provision of a wide range of medical products and supplies. The contract, valued at up to $30,953.15, is for the delivery of pharmaceutical products, including 4564615624 IPOL VIAL 5ML. This is a firm fixed price delivery order contract with a completion date of May 16, 2024. Amerisourcebergen holds a significant Indefinite Delivery...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $4,722.50 from the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other critical care items. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) is a delivery order valued at $4,190.10 under a larger $999,999,999 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The IDC, which runs through November 2026, enables Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The delivery order covers the provision...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB23FL21DDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $43,829.16 for the supply of IPOL VIAL 5ML pharmaceutical products. The contract was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense, and has a completion date of February 23, 2023. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. This particular Delivery Order is issued under that larger IDC. The contract does not have a set-aside designation, indicating it was awarded through full and open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $43.8k | 2/22/23 |